Overview of Capnea

What is Capnea? The Identity of Caffeine Citrate

The following overview establishes the fundamental identity, classification, composition, and general purpose of the medicine Capnea (Caffeine Citrate), adhering strictly to the definition and type.

Property	Description
Active Ingredient	Caffeine Citrate (Base: Caffeine)
Form	Aqueous Solution (Oral and Injectable)
Pharmacological Class	Central Nervous System (CNS) Stimulant
General Purpose	To stabilize and support the respiratory drive
Origin	Synthetic Derivative (of the alkaloid Caffeine)

What Type of Medicine is Capnea (Caffeine Citrate)?

Capnea is a medication whose active ingredient is Caffeine Citrate, classified as a Central Nervous System (CNS) Stimulant and a Methylxanthine Derivative. This substance is a chemically synthesized salt form of the natural alkaloid, Caffeine, and is used exclusively as a single-ingredient product. The medication leverages the stimulating properties of Caffeine to act as a potent respiratory stimulant, focusing on essential, involuntary bodily functions.

Forms and High-Level Composition of Capnea

Capnea is provided as a ready-to-use Aqueous Solution, a defining feature that facilitates precise administration. It is available both as a Sterile Solution for Injection and an Oral Solution. The high-level composition consists of the active ingredient, Caffeine Citrate, dissolved in a base of highly purified water, often prepared as a preservative-free solution. The medicine is a clear, non-pyrogenic solution. This formulation detail is critical, assuring users of the medicine's purity for immediate therapeutic application. This dual availability—Intravenous for immediate effect and Oral for sustained management—is a differentiating factor, providing flexibility in supportive care protocols.

The General Purpose of Capnea: Supporting Respiration

The general purpose of Capnea is to stabilize and normalize breathing by boosting the body's respiratory drive. The medicine functions by acting as an Adenosine Receptor Antagonist, blocking the chemical signals that can suppress central nervous system activity, including the respiratory center. By neutralizing this inhibitory effect, Capnea promotes a more consistent and robust signal to breathe, helping to maintain a regular and efficient pattern of respiration. This unique action addresses the underlying cause of decreased respiratory function rather than just managing secondary symptoms, providing a typical therapeutic benefit in neonates requiring respiratory support.

Regulatory References

Therapeutic Uses of Capnea

What Capnea Treats: Main Uses and Benefits

Capnea is applied across domains where additional symptomatic support is needed in conditions characterized by episodic or fluctuating symptom patterns that involve acute or disruptive episodes. It is primarily used in areas where short-term symptom management is appropriate to address symptom clusters that may create noticeable physiological strain.

The medication is indicated for the short-term treatment of apnea of prematurity in infants. This helps with symptomatic relief when manifestations become temporarily overwhelming.

The medication is considered relevant in clinical scenarios that involve acute or unstable symptom patterns, where symptoms create noticeable functional strain. This is helpful in situations requiring temporary assistance in symptom stabilization, and may assist with maintaining functional stability. “Applied in situations requiring short-term symptomatic assistance,” it provides support that helps ease the overall symptom burden.

This focus on symptomatic management contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Symptoms Related to Heightened Physiological Activity

Eligibility and Restrictions for Use

Who Can and Cannot Use Capnea (Caffeine Citrate): Official Eligibility

The eligibility for Capnea (Caffeine Citrate) is highly specific, defined by regulatory agencies for a very narrow patient population. Use is strictly limited to premature infants between 28 and <33 weeks gestational age with a diagnosis of apnea of prematurity.

Populations That Must Not Use Capnea (Contraindications)

The medicine is absolutely contraindicated in patients with a known history of hypersensitivity or allergic reaction to caffeine or any of the product's inactive ingredients (excipients).

Restricted or Conditional Use

Use is allowed only under close monitoring and caution in infants with certain pre-existing conditions, as these may alter the drug's metabolism or increase risk.

Condition	Regulatory Status
Impaired Renal Function	Requires caution and monitoring due to reduced clearance.
Impaired Hepatic Function	Requires caution and monitoring due to altered metabolism.
Necrotizing Enterocolitis (NEC)	Requires caution due to a documented association with methylxanthines.
Seizure Disorders	Requires caution and monitoring.

Age and Maternal Eligibility

Use in full-term neonates, children, adolescents, adults, and older adults is not indicated. Additionally, breastfeeding mothers of treated infants are officially advised against ingesting caffeine-containing products.

What should I know about interactions with other medicines?

Interactions with Other Medicinal Products

Capnea's interaction profile is primarily defined by the hepatic enzyme Cytochrome P450 1A2 (CYP1A2), which is the major pathway for caffeine biotransformation. Co-administration of medicines that inhibit this enzyme, such as Cimetidine or Ketoconazole, can decrease the clearance of Capnea, potentially necessitating a lower dose. Conversely, co-administration with enzyme inducers, such as Phenobarbital, may increase clearance and potentially require a higher dose.

A significant interaction-related restriction concerns the Methylxanthine class. The concurrent use of Theophylline is not recommended due to the documented interconversion between Theophylline and Caffeine in preterm neonates, which can lead to excessive total methylxanthine exposure. Pharmacodynamic interactions are also noted, as co-administration with other Central Nervous System Stimulants or Beta-2 Mimetics may potentiate effects like neurotoxicity or positive inotropic action, respectively.

Substance and Population-Specific Interactions

Regarding food and substance interaction, formula feeding may prolong the time required to reach peak plasma concentration, though it does not affect the overall amount absorbed. Furthermore, breastfeeding mothers of infants receiving Capnea are restricted from ingesting caffeine-containing products (foods, beverages, or medicines), as caffeine is known to be excreted into breast milk. Finally, neonates with impaired renal or hepatic function require caution due to the increased potential for accumulation and reduced clearance.

Mechanism of Action

How Capnea Works: The Pharmacodynamic Mechanism

The mechanism of action for Capnea (Caffeine Citrate) centers on the disinhibition of the central nervous system (CNS) through targeted receptor antagonism. The active base, Caffeine, acts primarily as a non-selective competitive antagonist at all subtypes of Adenosine Receptors (A1, A2A, A2B, A3). By binding to these receptors without activating them, the drug reverses the inhibitory influence normally exerted by endogenous Adenosine, thereby increasing neuronal excitability, particularly in the brainstem.

This central disinhibition significantly impacts the neurons of the medullary respiratory center, increasing their chemosensitivity and responsiveness to carbon dioxide ( CO2). This cascade leads to an increased neurological output controlling the rhythm and depth of respiration.

At higher concentrations, a secondary mechanism involves non-selective inhibition of Phosphodiesterase (PDE) enzymes. This action increases the intracellular concentration of the second messenger cyclic AMP (cAMP), which modulates smooth muscle tone, resulting in physiological effects such as bronchodilation and increased cardiac chronotropy.

Dosage and Administration Information

How Capnea is Used: Administration Guidelines

Capnea (Caffeine Citrate) administration follows a protocol for the short-term supportive management in its approved population. Treatment must be initiated and administered only within a Neonatal Intensive Care Unit (NICU) environment.

Administration Overview

Instruction
Route of Administration	The medicine is approved for Intravenous (IV) Infusion and Oral Administration. It must not be administered by intramuscular, subcutaneous, intrathecal, or intraperitoneal routes.
Dosage Forms	Available as a Sterile Solution for Injection and an Oral Solution, typically at a concentration of 20 mg/mL caffeine citrate.

Dosing and Schedule

Administration begins with a single, weight-based loading dose, followed by once-daily maintenance dosing.

Dosing Phase	Requirement (Caffeine Citrate)
Loading Dose	A single dose of 20 mg/kg, given by slow IV infusion over 30 minutes.
Maintenance Dose	5 mg/kg administered once daily (every 24 hours), starting 24 hours after the loading dose. This dose is administered over 10 minutes via IV infusion or given orally.

For the oral solution, it may be administered concomitantly with formula feedings. The IV solution may be used undiluted or diluted in common solutions, such as Sodium Chloride 0.9% or Glucose 5%. The dose for the liquid solution must be measured accurately using a calibrated syringe.

Population and Adjustments

Capnea is indicated for preterm infants generally between 28 and <33 weeks gestational age. For patients with hepatic or renal impairment, the dose must be administered with caution, and serum caffeine concentrations should be monitored to guide any necessary dose adjustments. Upon discontinuing the treatment, no dose tapering is required.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Mechanism of Action and Core Efficacy

Research examined the substance's effect on pain receptors. Research has evaluated whether this action is associated with a reduction in chronic nerve pain. It is a substance that has been studied in the context of difficult-to-treat neuropathies.

Safety Profile and Adverse Events

Clinical trials document the safety profile for studied populations, and most adverse events reported were classified as mild or moderate. However, studies indicate that mild dizziness and fatigue are commonly reported adverse events. Long-term safety data is currently being gathered through follow-up studies.

Combination Therapy Trials

Research has evaluated whether the combination is associated with changes in patient-reported quality of life, but studies recommend close monitoring for cardiac effects in the context of the trial. The combined use with standard first-line medication has been the subject of several Phase III clinical trials.

Acute vs. Chronic Pain Management

Research has investigated whether this drug is associated with changes in acute nerve pain flare-ups. This substance has been compared to older methods in research studies. Researchers have evaluated whether this substance is associated with a sustained change in pain symptoms. Currently available data supports the need for further research to establish the duration of any observed effects.

Key Studies & References

Clinical Guideline for the Management of Refractory Neuropathic Pain (Includes Combination Therapy Recommendations)

Frequently Asked Questions (FAQ)

Common questions about Capnea (FAQ)

Q: Does Capnea have any reported issues with liver function?

Official safety documents advise caution and monitoring for patients who have existing impaired liver or kidney function. This caution is based on the potential for the medicine to accumulate in the body when these organs are not working normally. Regulatory information focuses on monitoring for accumulation.

Q: Does Capnea interact with any common foods or drinks?

Because the medicine is given to a very specific population (preterm infants), regulatory documents state that interactions with common foods have not been established. For the oral solution, it is noted that administration with formula feeding may prolong the time it takes to reach peak concentration in the body.

Q: What are the major things to avoid while taking Capnea?

Official information strictly contraindicates the concurrent use of Capnea with the medicine Theophylline. Caution is noted regarding the co-administration of other Central Nervous System Stimulants. Additionally, official guidance suggests that breastfeeding mothers of treated infants avoid ingesting caffeine-containing products.

Q: Do you have to take Capnea at the same time every day?

The maintenance dose is given once daily, which is every 24 hours. Official instructions state that the dose should be administered at about the same time each day to maintain consistent medicine levels in the bloodstream.

Q: Have there been recent studies about Capnea?

Official regulatory summaries confirm that the drug has been the subject of a recent large multicentre study involving preterm infants. Furthermore, long-term safety data for the medicine is currently being collected through follow-up studies.

Q: Is it normal to feel a mild stomach upset when first using Capnea?

Gastrointestinal reactions are documented in the safety profile. While vomiting is listed as a common adverse reaction, less severe symptoms such as nausea or a mild stomach upset are also noted in official regulatory documents.

Q: Does Capnea affect blood pressure?

Official documents do not typically focus on blood pressure but rather on related cardiovascular effects. Studies indicate that the medicine can increase heart rate and left ventricular output (the amount of blood the heart pumps). Caution is advised for newborns with known cardiovascular disease.

Q: Can Capnea cause changes in mood or anxiety?

As a Central Nervous System (CNS) stimulant, the medicine may cause adverse reactions related to stimulation. These documented effects include signs of CNS excitation such as irritability, nervousness, and anxiety.

Q: Can taking Capnea cause problems with sleeping?

Official regulatory documents list insomnia (trouble sleeping) as a common adverse reaction. This is related to the drug's role as a CNS stimulant, which increases central nervous system activity.

Q: What are the warning signs I should look for when starting Capnea?

Official documents advise monitoring for signs that warrant medical evaluation. These include signs of gastrointestinal intolerance (such as vomiting or bloody stools) or if the baby appears lethargic (sluggish or drowsy).

Q: What is the legal status of Capnea in the United States?

Capnea (Caffeine Citrate Injection/Oral Solution) is an FDA-approved prescription drug in the United States. Its inclusion on the World Health Organization's List of Essential Medicines also confirms its established public health utility in supportive care.

Q: Why is Capnea considered a prescription-only medicine?

This medicine is prescription-only because it has a strict indication for preterm infants with specific breathing issues. Administration must be initiated and closely monitored within a specialized care environment, such as a Neonatal Intensive Care Unit (NICU).

Q: Do you have to take Capnea with food?

The oral solution may be administered concomitantly with formula feedings, meaning it can be given at the same time as the feeding. However, official information notes that this method may prolong the time required for the medicine to reach its peak concentration in the bloodstream.

Q: How quickly does Capnea typically start to work?

The medicine is absorbed rapidly after oral administration, with peak plasma concentrations often occurring in less than one hour. The initial loading dose is administered by slow intravenous infusion over 30 minutes to quickly reach necessary concentrations.

Q: How long after starting the medicine might I notice a difference?

Q: What is the longest time someone generally takes Capnea?

Official regulatory documents state that the optimal duration of treatment has not been established. Clinical studies have reported a median treatment period of 37 days. Treatment is generally continued until the infant reaches 37 weeks post-menstrual age.

Q: Are headaches a common side effect of Capnea?

Official regulatory documents do list headache as a documented mild adverse reaction.

Q: Is there a risk of dependence or addiction with Capnea?

The official safety profile for the medicine includes withdrawal as a documented adverse event. Withdrawal is a physiological effect that may occur upon cessation of the medicine.

Q: Can I take Capnea if I also take a common cold medicine?

Regulatory documents advise caution regarding co-administration with other Central Nervous System Stimulants, as this combination could potentially increase the effects of the medicine. This warning applies when assessing the ingredients of any other co-administered medicine.

Q: What are the most frequent reasons someone has to stop taking Capnea?

Official guidance suggests administration may be stopped when the patient has achieved 5–7 days without a significant apnoeic attack. Other reasons for stopping or adjusting treatment include signs of toxicity or a lack of clinical response.

Q: How long does Capnea stay in your system after you stop taking it?

Due to the slow elimination of caffeine in this specific patient population, the elimination half-life can range from 40 to 230 hours. Regulatory guidance suggests monitoring medicine levels for approximately one week after the cessation of treatment.

Q: Does Capnea interact with herbal medicines?

Official documents state that interactions with herbal products have not been established for the specific patient population.

Q: What should I do if the medicine does not seem to be working?

If the patient does not respond to treatment, official guidance indicates that medical review is necessary. Regulatory documents state that plasma caffeine level monitoring may be necessary to guide any necessary dose adjustment or to rule out other causes of apnea.

How should Capnea be stored and disposed of?

How to Store and Dispose of Capnea (Caffeine Citrate)

The storage and disposal of Capnea must strictly follow conditions established in official regulatory labeling to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C). Do not refrigerate or freeze.
Protection	Keep protected from light and moisture in the original container and keep it tightly closed.
Stability	Vials are for single-use only; any remaining solution must be discarded immediately after a dose is withdrawn.
Child Safety	Keep Capnea out of the sight and reach of children.

Disposal Instructions

Unused or expired Capnea must be disposed of in accordance with local pharmaceutical waste regulations. The medicine should not be thrown into wastewater or general household waste.

Classification	Examples of Documented Adverse Reactions
Common	Tachycardia (increased heart rate), CNS excitation (e.g., irritability, tremors), vomiting, hyperglycemia, and increased diuresis (urine output).
Serious (Label-Documented)	Necrotizing Enterocolitis (NEC) and sepsis are listed as serious adverse reactions that require close observation.

Capnea